Mount Sinai researchers publish landmark cell review defining the “hallmarks of liver cancer”
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Jun-2026 22:16 ET (22-Jun-2026 02:16 GMT/UTC)
A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.
A new study has identified a molecular guardian that keeps skin cells from "forgetting" what they are and transforming into aggressive, migratory killers. By stabilizing a master genetic switch, this protein shield prevents common skin tumors from undergoing a dangerous metamorphosis and spreading to the lungs.
Gallbladder cancer (GBC) is a rare form of cancer with no signs or symptoms in the early stages. In the U.S., approximately 2,000 people die annually from this condition, with only 20% diagnosed at an early stage. Surgery remains the most effective treatment. Although minimally invasive approaches—laparoscopic and robotic are increasingly used in gastrointestinal oncology, their use in GBC is limited and comparing robotic surgery to laparoscopic and conventional surgery approaches remains limited and controversial.
In a new review in the journal Surgical Oncology Clinics, BU researchers show that minimally invasive surgery—especially robotic surgery—can be a safe way to treat selected patients with gallbladder cancer. In the studies reviewed, robotic approaches often had less blood loss, shorter hospital stays, and sometimes removed more lymph nodes, while long‑term cancer outcomes resembled those for open surgery in appropriately chosen patients.